Laprophan
Active · Morocco
Source: Deutsche Investitions- und Entwicklungsgesellschaft (DEG)
Laprophan, established in 1949, is a leading pharmaceutical company in Morocco that operates across the complete value chain comprising R&D, manufacturing, licensing/registration and distribution. Whereas Laprophan´s own products are focussed around primary care and low cost generics, the portfolio is complemented by imported products not locally produced. Laprophan is a mid-size family owned comp
- Status
- Prospective
- Sector
- Government, Manufacturing (Industrial), Power Generation (CCGT), Solar
- Location
- Morocco
- Updated
- 19 Nov 2026
- Source
- Deutsche Investitions- und Entwicklungsgesellschaft (DEG)
ConstructChat
Ask ConstructChat about Laprophan
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | active |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Laprophan, established in 1949, is a leading pharmaceutical company in Morocco that operates across the complete value chain comprising R&D, manufacturing, licensing/registration and distribution. Whereas Laprophan´s own products are focussed around primary care and low cost generics, the portfolio is complemented by imported products not locally produced. Laprophan is a mid-size family owned company with Farid Bennis holding the majority of the shares.DEG, along with FMO, Proparco and fund Partner Mediterranea Capital, will invest up to USD 14.5m in common shares to finance the construction of a new state of the art pharma plant and other future growth initiatives. Part of the funding will be utilized to buy out of family members, with the purpose of enabling the company to focus on developing the business.The developmental impact of the project is high. Laprophan’s core business, primary care and affordable generics, addresses the basic needs of the poorer and underserved local population. Laprophan’s strategy is complementary to the strategic priority of the Moroccan government to make healthcare coverage universal and increase access to affordable, locally produced medicines in Morocco. Furthermore, Laprophan’s new, state of the art factory will contribute to increased efficiency in the Moroccan pharma industry which results in improvements of the healthcare system. The transaction strongly contributes to SDG 3 (Good Health and Well-Being) and SDG 9 (Industry, Innovation and Infrastructure).The role of DEG in the transaction is important. Without DFI funding the transaction would not materialize as sufficient private funding cannot be mobilized at this stage. DEG will also play an important role with respect to the implementation of international E&S standards, the improvement of corporate governance and the progression of the family owned company towards more institutionalization.The transaction fits well with DEG’s strategy to support high impact businesses, in this case a company that produces low cost generic drugs that serve the basic needs of the poorer population. Additionally, the project will reduce the CO2 footprint as the new state of the art factory and the installation of solar power system will result in reduced energy consumption. |
Original sector | Industry |
Budget |
Location
Country | Morocco |
Source
Source | Deutsche Investitions- und Entwicklungsgesellschaft (DEG) |
URL |
More Details
Record type | Project |
Sector | Government, Manufacturing (Industrial), Power Generation (CCGT), Solar |
Article published date | 2024-05-29 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
